跳至主要内容
临床试验/NCT05718791
NCT05718791招募中不适用

CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease

Henry Ford Health System1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年5月10日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
predictors of acute GVHD

研究概览

简要总结

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients >18 year old admitted for allo SCT PB for malignant disease.

排除标准

  • 未提供

结局指标

主要结局

predictors of acute GVHD

时间窗: CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.

CXCL9 combined with EASIX can be used as predictors of acute GVHD

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shatha Farhan

Clinical Assistant Professor

Henry Ford Health System

研究点 (1)

Loading locations...

相似试验